科研方向及学术成果：
利用蛋白质组学技术，研究疾病发生和药物作用的分子机制，建立重大疾病的生物标志物图谱及其辅助分类系统。同时，致力于多价态、长效化蛋白质药物的构建和基于高分辨质谱的表征评价，并以此进行创新蛋白质药物的研发和工程化细胞的改造，实现对肿瘤等重大慢性疾病的诊断和干预。以第一或通讯作者在PNAS、Nucleic Acids Research、Biomaterials、Theranostics、Journal of Controlled Release、Molecular & Cellular Proteomics等本领域高水平期刊发表重要论文30余篇，包括3篇封面论文和1篇ESI高被引论文。获授权中国发明专利10项，美国发明专利1项。主持科技部重点研发计划子课题、国家自然科学基金面上项目、NSFC青年基金和省科技厅国际合作项目等研究。作为主研人员，先后参与国家临床重点专科项目、国家科技部重点研发计划等多项重要研究。近5年获准重要国家级项目：
1. 国家重点研发计划子课题任务，2021YFF0702003-02，基于新靶点的重大传染病人源化动物模型研发：疾病动物模型的分子表型数据库及评价技术平台建设，2021/12-2025/11，任务负责人
2. 国家自然科学基金面上项目，82173727，死亡受体DR5六聚体激动剂的定制及其抗肿瘤作用研究，2022/01-2025/12，主持
3. 国家自然科学基金面上项目，81871475，纳米递送系统表面修饰靶向促凋亡配体Z-TRAIL共递送双硫仑的协同抗肿瘤作用和机制研究，2019/01-2022/12，主持
近5年代表性论文：
1. Yang H#, Li H#, Yang F, Tao Z, Shi Q, She T, Feng Y, Li Z, Chen J, Zhong Y, Su T, Zeng W, Zhang Y, Wang S, Li L, Long T, Long D, Cheng J, Zhu H*, Lu X*. Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity. Biomaterials. 2023:121994.
2. Wei DF, Qi JX, Wen X, Hamblin MR, Jiang X*, Yang H*. Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond. Theranostics. 2022;12(16):7108-7131
3. Zhong Y, Yang F, Su T, Wu X, Zheng W, Zhang L, Liang G, Wang L, Wang L*, Wang S*, Yang H. Proteome and phosphoproteome profiling of non-small cell lung cancer cell line A549 treated with TRAIL. Proteomics. 2022:e2200248
4. Zhang D, Jiang L, Li L, Li X, Zheng W, Gui L, Yang Y, Liu Y, Yang L, Wang J, Xiong Y, Ji L, Deng Y, Liu X, He Q, Hu X, Liu X, Fan R, Lu Y, Liu J, Cheng J, Yang H, Li T*, Gong M*. Integrated metabolomics revealed the fibromyalgia-alleviation effect of Mo2C nanozyme through regulated homeostasis of oxidative stress and energy metabolism. Biomaterials. 2022;287:121678.
5. Wang M, Zhang Z, Liu J, Song M, Zhang T, Chen Y, Hu H, Yang P, Li B, Song X, Pang J, Xing Y, Cao Z, Guo W, Yang H, Wang J*, Yang J*, Wang C. Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration. Signal Transduct Target Ther. 2022;7(1):157.
6. Yu H, Luo H, Chang L, Wang S, Geng X, Kang L, Zhong Y, Cao Y, Wang R, Yang X, Zhu Y, Shi MJ, Hu Y, Liu Z, Yin X, Ran Y, Yang H*, Fan W*, Zhao BQ*. The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice. Proc Natl Acad Sci USA. 2022;119(6).
7. Yang Y, Cheng J, Wang S*, Yang H*. StatsPro: Systematic integration and evaluation of statistical approaches for detecting differential expression in label-free quantitative proteomics. J Proteomics. 2022;250:104386.
8. She T, Shi Q, Li Z, Feng Y, Yang H, Tao Z, Li H, Chen J, Wang S, Liang Y, Cheng J*, Lu X*. Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer. Theranostics. 2021;11(9):4281-4297.
9. Liu F, Yang W, Hu M, Zhang Y, Sun B, Yang H*, Brosius J*, Deng C*. Constitutive activity of GPR26 regulated by ubiquitin-dependent degradation and its antitumor role. FEBS J. 2021;288(15):4655-4682
10. Fan J, Feng Y, Tao Z, Chen J, Yang H, Shi Q, Li Z, She T, Li H, Jin Y, Cheng J*, Lu X*. A versatile platform for the tumor-targeted delivery of immune checkpoint-blocking immunoglobin G. J Control Release. 2021;340:243-258.
11. Zhao L, Zhang Y, Liu F*, Yang H*, Zhong Y, Wang Y, Li S, Su Q, Tang L, Bai L, Ren H, Zou Y, Wang S, Zheng S, Xu H, Li L, Zhang J, Chai Z, Cooper ME, Tong N. Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. J Endocrinol Invest. 2021;44(12):2709-2723.
12. Zhang Y, Zheng S, Zhao W, Mao Y, Cao W, Zeng W, Liu Y, Hu L, Gong M, Cheng J, Chen Y*, Yang H*. Sequential Analysis of the N/O-Glycosylation of Heavily Glycosylated HIV-1 gp120 Using EThcD-sceHCD-MS/MS. Front Immunol. 2021;12:755568.
13. Zhang Y, Zheng S, Mao Y, Cao W, Zhao L, Wu C, Cheng J, Liu F*, Li G*, Yang H*. Systems analysis of plasma IgG intact N-glycopeptides from patients with chronic kidney diseases via EThcD-sceHCD-MS/MS. Analyst. 2021;146(23):7274-7283.
14. Zhang Y, Zhao W, Mao Y, Chen Y, Zheng S, Cao W, Zhu J, Hu L, Gong M, Cheng J*, Yang H*. O-Glycosylation Landscapes of SARS-CoV-2 Spike Proteins. Front Chem. 2021;9:689521.
15. Zhang Y, Zhao W, Mao Y, Chen Y, Wang S, Zhong Y, Su T, Gong M, Du D, Lu X, Cheng J*, Yang H*. Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins. Mol Cell Proteomics. 2021;20:100058. ESI高被引论文
16. Zeng W, Zheng S, Mao Y, Wang S, Zhong Y, Cao W, Su T, Gong M, Cheng J, Zhang Y*, Yang H*. Elevated N-Glycosylation Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells Revealed by Membrane Proteomic and Glycoproteomic Analysis. Front Pharmacol. 2021;12:805499.
17. Zhang Y, Zhao W, Zhao Y, Mao Y, Su T, Zhong Y, Wang S, Zhai R, Cheng J, Fang X*, Zhu J*, Yang H*. Comparative Glycoproteomic Profiling of Human Body Fluid between Healthy Controls and Patients with Papillary Thyroid Carcinoma. J Proteome Res. 2020;19(7):2539-2552. 当期封面论文
18. Zhang Y, Mao Y, Zhao W, Su T, Zhong Y, Fu L, Zhu J, Cheng J, Yang H*. Glyco-CPLL: An Integrated Method for In-Depth and Comprehensive N-Glycoproteome Profiling of Human Plasma. J Proteome Res. 2020;19(2):655-666.
19. Zhang Y, Lin T, Zhao Y, Mao Y, Tao Y, Huang Y, Wang S, Hu L, Cheng J*, Yang H*. Characterization of N-linked intact glycopeptide signatures of plasma IgGs from patients with prostate carcinoma and benign prostatic hyperplasia for diagnosis pre-stratification. Analyst. 2020;145(15):5353-5362.
20. Wei D, Tao Z, Shi Q, Wang L, Liu L, She T, Yi Q, Wen X, Liu L, Li S, Yang H*, Jiang X*. Selective Photokilling of Colorectal Tumors by Near-Infrared Photoimmunotherapy with a GPA33-Targeted Single-Chain Antibody Variable Fragment Conjugate. Mol Pharm. 2020;17(7):2508-2517.
21. Wang S, Zhu H, Zhou H, Cheng J*, Yang H*. MSpectraAI: a powerful platform for deciphering proteome profiling of multi-tumor mass spectrometry data by using deep neural networks. BMC Bioinformatics. 2020;21(1):439.
22. Wang S, Li W, Hu L, Cheng J, Yang H*, Liu Y*. NAguideR: performing and prioritizing missing value imputations for consistent bottom-up proteomic analyses. Nucleic Acids Res. 2020;48(14):e83.
23. Fan Q, Tao Z, Yang H, Shi Q, Wang H, Jia D, Wan L, Zhang J, Cheng J, Lu X. Modulation of pericytes by a fusion protein comprising of a PDGFRbeta-antagonistic affibody and TNFalpha induces tumor vessel normalization and improves chemotherapy. J Control Release. 2019;302:63-78.
24. Zhong Y, Su T, Shi Q, Feng Y, Tao Z, Huang Q, Li L, Hu L, Li S, Tan H, Liu S*, Yang H*. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment. Int J Nanomedicine. 2019;14:8543-8560.
25. Wang S, Yang H*. pseudoQC: A Regression-Based Simulation Software for Correction and Normalization of Complex Metabolomics and Proteomics Datasets. Proteomics. 2019;19(19):e1900264.
26. Wang S, Cai Y, Cheng J, Li W, Liu Y*, Yang H*. motifeR: An Integrated Web Software for Identification and Visualization of Protein Posttranslational Modification Motifs. Proteomics. 2019;19(23):e1900245.
27. Yang H#, Feng Y#, Cai H, Jia D, Li H, Tao Z, Zhong Y, Li Z, Shi Q, Wan L, Li L, Lu X*. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects. Theranostics. 2018;8(9):2459-2476.
28. Tao Z#, Yang H#, Shi Q, Fan Q, Wan L, Lu X*. Targeted Delivery to Tumor-associated Pericytes via an Affibody with High Affinity for PDGFRbeta Enhances the in vivo Antitumor Effects of Human TRAIL. Theranostics. 2017;7(8):2261-2276. 当期封面论文
29. Li R#, Yang H#, Jia D, Nie Q, Cai H, Fan Q, Wan L, Li L, Lu X*. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J Control Release. 2016;228:96-106. 当期封面论文
30. Su T#, Yang H#, Fan Q, Jia D, Tao Z, Wan L, Lu X*. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier. Int J Pharm. 2016;499(1-2):195-204.
